Cgs 26303

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412774

CAS#: 154116-31-1

Description: Cgs 26303 is a potent non-peptidic inhibitor of neutral endopeptidase capable of protecting atrial natriuretic peptide from enzymatic degradation.

Chemical Structure

img
Cgs 26303
CAS# 154116-31-1
Instruction

Theoretical Analysis

MedKoo Cat#: 412774
Name: Cgs 26303
CAS#: 154116-31-1
Chemical Formula: C16H18N5O3P
Exact Mass: 359.11
Molecular Weight: 359.330
Elemental Analysis: C, 53.48; H, 5.05; N, 19.49; O, 13.36; P, 8.62

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Cgs 26303; Cgs26303; Cgs-26303

IUPAC/Chemical Name: Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, (S)-

InChi Key: UUMKQZVEZSXWBY-HNNXBMFYSA-N

InChi Code: InChI=1S/C16H18N5O3P/c22-25(23,24)11-17-15(16-18-20-21-19-16)10-12-6-8-14(9-7-12)13-4-2-1-3-5-13/h1-9,15,17H,10-11H2,(H2,22,23,24)(H,18,19,20,21)/t15-/m0/s1

SMILES Code: OP(CN[C@H](C1=NN=NN1)CC2=CC=C(C3=CC=CC=C3)C=C2)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 359.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wang HC, Cheng KI, Chou CW, Kwan AL, Chang LL. Intrathecal CGS-26303 Pretreatment Attenuates Spinal Nerve Ligation-Induced Neuropathic Pain in the Spinal Cord. World Neurosurg. 2016 Jul;91:532-541.e1. doi: 10.1016/j.wneu.2016.02.093. Epub 2016 Mar 4. PMID: 26947729.

2: Raoch V, Martinez-Miguel P, Arribas-Gomez I, Rodriguez-Puyol M, Rodriguez- Puyol D, Lopez-Ongil S. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1. Br J Pharmacol. 2007 Oct;152(3):313-22. doi: 10.1038/sj.bjp.0707398. Epub 2007 Jul 23. PMID: 17643133; PMCID: PMC2042959.

3: Chang CZ, Yen CP, Winadi D, Wu SC, Howng SL, Lin TK, Jeng AY, Kassell NF, Kwan AL. Neuroprotective effect of CGS 26303, an endothelin-converting enzyme inhibitor, on transient middle cerebral artery occlusion in rats. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S487-9. doi: 10.1097/01.fjc.0000166307.86678.d1. PMID: 15838355.

4: Wang CJ, Lee PY, Wu BN, Wu SC, Loh JK, Tsai HP, Chung CL, Kassell NF, Kwan AL. Alteration of basilar artery rho-kinase and soluble guanylyl cyclase protein expression in a rat model of cerebral vasospasm following subarachnoid hemorrhage. Biomed Res Int. 2014;2014:531508. doi: 10.1155/2014/531508. Epub 2014 Jun 1. PMID: 24982890; PMCID: PMC4058103.

5: Lin CL, Kwan AL, Dumont AS, Su YF, Kassell NF, Wang CJ, Wu SC, Kuo CL, Huang CS, Jeng AY, Liu CS. Attenuation of experimental subarachnoid hemorrhage-induced increases in circulating intercellular adhesion molecule-1 and cerebral vasospasm by the endothelin-converting enzyme inhibitor CGS 26303. J Neurosurg. 2007 Mar;106(3):442-8. doi: 10.3171/jns.2007.106.3.442. PMID: 17367067.

6: Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension. 2005 Jun;45(6):1145-52. doi: 10.1161/01.HYP.0000168944.29525.da. Epub 2005 May 16. PMID: 15897363.

7: Yen CP, Chen SC, Lin TK, Wu SC, Chang CY, Lue SI, Jeng AY, Kassell NF, Kwan AL. CGS 26303 upregulates mRNA expression of heme oxygenase-1 in brain tissue of rats subjected to experimental subarachnoid hemorrhage. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S474-8. doi: 10.1097/01.fjc.0000166310.71431.52. PMID: 15838352.

8: Henry PJ, Carr MJ, Goldie RG, Jeng AY. The role of endothelin in mediating virus-induced changes in endothelinB receptor density in mouse airways. Eur Respir J. 1999 Jul;14(1):92-7. doi: 10.1034/j.1399-3003.1999.14a16.x. PMID: 10489834.

9: Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol. 2004 Apr;43(4):489-94. doi: 10.1097/00005344-200404000-00003. PMID: 15085059.

10: Jeng AY, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Trapani AJ. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S36-9. doi: 10.1097/00005344-200036051-00014. PMID: 11078330.